Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis

Yung Tai Chen, Hung Ta Chen, Chien Yi Hsu, Pei Wen Chao, Shu Chen Kuo, Shuo Ming Ou, Chia Jen Shih

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


Background and objectives We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis. Design, setting, participants, & measurements A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan’s National Health Insurance Research Database for the period 2007–2011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score–adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with ≤6 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding. Results In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95% confidence interval, 0.36 to 0.81; P=0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95% confidence interval, 0.75 to 3.04). In the propensity score–adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use. Conclusions Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.

Original languageEnglish
Pages (from-to)262-271
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Issue number2
Publication statusPublished - 2017


  • 2’-deoxythymidylyl-(3’-5’)-2’-deoxyadenosine
  • Cohort
  • Coronary artery disease
  • Drug-eluting stents
  • Epidemiology and outcomes
  • Hemodialysis
  • Hemorrhage
  • Humans
  • Myocardial infarction
  • National health programs
  • Odds ratio
  • Propensity score
  • Renal dialysis
  • Risk assessment
  • Stroke
  • Studies
  • Taiwan
  • Treatment outcome

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation


Dive into the research topics of 'Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis'. Together they form a unique fingerprint.

Cite this